



## Delivered Strong Financial and Operational Performance

### TOTAL NET SALES

**\$46.2B**

Consistent with prior year or, an increase of 3% when excluding foreign exchange

**7%** In-Line Brand YoY% growth

**87%** New Product Portfolio\* YoY% growth

Potential for risk-adjusted sales of **\$10-\$13B** revenues in 2025

Potential for **\$25B+** of non-risk-adjusted revenues in 2030

### GAAP EPS<sup>1</sup>

**\$2.95**

### Non-GAAP EPS<sup>1,2</sup>

**\$7.70**

\* New Product Portfolio includes *Reblozyl*® (luspatercept-aamt), *Inrebic*® (fedratinib), *Onureg*® (azacitidine tablets), *Zeposia*® (ozanimod), *Breyanzi*® (lisocabtagene maraleucel), *Abecma*® (idecabtagene vicleucel), *Opdualag*® (relatlimab plus nivolumab), *Camzyos*® (mavacamten) and *Sotykytu*™ (deucravacitinib).

<sup>1</sup> GAAP and non-GAAP EPS include the net impact of Acquired IPRD charges and licensing income of (\$0.24) per share for the full year 2022. Acquired IPRD refers to certain in-process research and development ("Acquired IPRD") charges resulting from upfront or contingent milestone payments in connection with asset acquisitions or licensing of third-party intellectual property rights.

<sup>2</sup> This Non-GAAP amount excludes certain costs, expenses, gains and losses and other specified items. A reconciliation of GAAP to non-GAAP measures can be found on our website at bms.com. See, "Quarterly package of financial information" available on bms.com/investors for information on the list of specified items excluded from Non-GAAP EPS.

<sup>3</sup> Portfolio achievements from 2H 2019-2022.

<sup>4</sup> Includes \$4.6 billion for dividends paid and \$8.0 billion for common stock repurchases.

## Significant Pipeline Advancement in 2022

**18** approvals in the US, EU and Japan

**9** approvals for *Opdivo*; *Opdivo plus Yervoy*



**5** positive registrational topline readouts

**\$9.5B**

invested in research and development

## Launched 3 First-In-Class Medicines

**Opdualag**  
(nivolumab and relatlimab-rmbw)  
Injection for intravenous use | 480 mg/160 mg

For metastatic melanoma

**CAMZYOS**  
(mavacamten) capsules

For obstructive hypertrophic cardiomyopathy

**SOTYKTU**  
(deucravacitinib) 6 mg tablets

For moderate to severe plaque psoriasis

## Strategically Positioned for Multiple Waves of Innovation

**9** new products launched over ~3 years<sup>3</sup>

**15+**



additional indications over ~3 years<sup>3</sup>

**6** high potential mid-late stage registrational assets across therapeutic areas

**50+**



early-stage assets in development

## Balanced Approach to Capital Allocation

**\$13.1B**

in cash flow from operating activities

Reduced debt by

**~\$5B**

Returned cash to shareholders

**\$12.6B<sup>4</sup>**